Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
78 hedge funds and large institutions have $55.6M invested in Adverum Biotechnologies in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 29 reducing their positions, and 15 closing their positions.
12,800% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $10K
1% more funds holding
Funds holding: 77 → 78 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 5.9% → 5.89% (-0%)
21% less capital invested
Capital invested by funds: $70M → $55.6M (-$14.4M)
62% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.34M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.58M |
| 3 |
AC
Antara Capital
New York
|
+$1.41M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$665K |
| 5 |
CCM
CAAS Capital Management
New York
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$3.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.07M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.26M |
| 4 |
Two Sigma Advisers
New York
|
-$595K |
| 5 |
JP Morgan Chase
New York
|
-$548K |
ADVM Hedge Fund Activity: Q3 2022 in Review
78 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2022, worth a combined $55.6M — down 21% from $70M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADVM positions and 15 closed out — a net gain of 1 holder — while 11 added to existing stakes and 29 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $7.34M. The largest seller was Artal Group, exiting entirely with an estimated $3.6M sold.
- 78 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2022, up from 77 in Q2 2022.
- Funds reported $55.6M of Adverum Biotechnologies stock for Q3 2022, down 21% quarter-over-quarter.
- 16 funds opened new Adverum Biotechnologies positions in Q3 2022 and 15 closed out, a net change of +1 holder.
- The largest Adverum Biotechnologies buyer in Q3 2022 was Soleus Capital Management, an estimated $7.34M added.
- The largest Adverum Biotechnologies seller in Q3 2022 was Artal Group, an estimated $3.6M sold.
Based on aggregated 13F filings for Q3 2022.